MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS

• US 20160304864A1
• Filed: 01/07/2016
• Published: 10/20/2016
• Est. Priority Date: 10/26/2007
• Status: Abandoned Application

• Current Assignee: Academisch Ziekenhuis Leiden, Biomarin Pharmaceutical Incorporated (Amgen Inc.), BioMarin Technologies B.V.
• Original Assignee: Academisch Ziekenhuis Leiden, BioMarin Technologies B.V.
• Inventors: De KIMPE, Josephus Johannes, PLATENBURG, Gerard Johannes, Van DEUTEKOM, Judith Christina Theodora, AARTSMA-RUS, Annemieke, Van OMMEN, Garrit-Jan Boudewijn
• Application Number:
  US14/990,712
• Publication Number:
  US 20160304864A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 38/1719 Muscle proteins, e.g. myosin or actin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/111 spanning the whole gene, or a large part of it
• CPC Class Codes: C12N 2310/31 : of the backbone
• CPC Class Codes: C12N 2310/313 : Phosphorodithioates
• CPC Class Codes: C12N 2310/314 : Phosphoramidates
• CPC Class Codes: C12N 2310/315 : Phosphorothioates
• CPC Class Codes: C12N 2310/3181 : Peptide nucleic acid, PNA
• CPC Class Codes: C12N 2310/321 : 2'-O-R Modification
• CPC Class Codes: C12N 2310/3231 : having an additional ring, e.g. LNA, ENA
• CPC Class Codes: C12N 2310/3233 : Morpholino-type ring
• CPC Class Codes: C12N 2310/346 : having a combination of backbone and sugar modifications
• CPC Class Codes: C12N 2310/3521 : Methyl
• CPC Class Codes: C12N 2320/31 : Combination therapy
• CPC Class Codes: C12N 2320/33 : Alteration of splicing

Abstract

The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.

Claims

1. A composition comprising:

a first compound that increases the level of a functional dystrophin protein produced in a muscle cell of a Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) individual,

wherein said first compound is an antisense oligonucleotide that induces skipping of an exon of human dystrophin pre-mRNA of said individual; and

a second compound comprising a steroid;

wherein, upon administration to a DMD or BMD patient, the composition increases the ratio of said dystrophin to laminin-α

2 in muscle tissue of said patient as compared to the ratio of said dystrophin to laminin-α

2 in muscle tissue of a patient administered with said first compound and not said second compound; and

wherein said antisense oligonucleotide is complementary to a portion of said exon selected from the group consisting of;

exon 2, exon 8, exon 43, exon 44, exon 45, exon 46, exon 50, exon 52, exon 53 and exon 55, that is 13 to 50 nucleotides in length and

wherein said oligonucleotide comprises a non-naturally occurring modification

2. The composition of claim 1, wherein said antisense oligonucleotide is complementary to a portion of the exon that is 14 to 25 nucleotides in length.

3. The composition of claim 1, wherein said antisense oligonucleotide is complementary to a portion of the exon that is 20 to 25 nucleotides in length.

4. The composition of claim 1, wherein said antisense oligonucleotide comprises one or more ribonucleotides, and wherein a said ribonucleotide contains a modification.

5. The composition of claim 4, wherein said modification is a 2′

-O-methyl modified ribose.

6. The composition of claim 1, wherein said modification is selected from the group consisting of at least one of a peptide nucleic acid, a locked nucleic acid, and morpholino phosphorodiamidate.

12. A pharmaceutical preparation comprising:

said first compound according to claim 1, said second compound according to claim 1, comprising a steroid, and a pharmaceutically acceptable carrier, adjuvant, diluent and/or excipient.

13. A kit comprising:

said first compound according to claim 1, and said second compound according to claim 1.

14. The kit of claim 13, further comprising a pharmaceutically acceptable carrier, adjuvant, diluent and/or excipient.

15. The kit of claim 13, further comprising packaging means thereof.

16. The composition according to claim 1, wherein the oligonucleotide comprises a phosphorothioate internucleotide linkage, a 2′

-O-methyl ribose and/or a LNA.

17. The kit according to claim 13, wherein the oligonucleotide comprises a phosphorothioate internucleotide linkage, a 2′

-O-methyl ribose and/or a LNA.

18. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier, adjuvant, diluent, and/or excipient.

7. A method for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy or Becker Muscular Dystrophy in an individual, the method comprising administering to a DMD or BMD patient:

a first compound that increases the level of a functional dystrophin protein produced in a muscle cell of said individual in said individual,

wherein said first compound is an antisense oligonucleotide that induces skipping of an exon selected from the group consisting of;

exon 2, exon 8, exon 43, exon 44, exon 45, exon 46, exon 50, exon 52, exon 53 and exon 55 of the dystrophin pre-mRNA of said individual, and

a second compound, comprising a steroid;

wherein, upon administration to a DMD or BMD patient, the composition increases the ratio of said dystrophin to laminin-α

2 in muscle tissue of said patient as compared to the ratio of said dystrophin to laminin-α

2 in muscle tissue of a patient administered with said first compound and not said second compound; and

wherein said antisense oligonucleotide is complementary to a portion of the exon that is 13 to 50 nucleotides in length and wherein said oligonucleotide comprises a non-naturally occurring modification.

8. The method of claim 7, wherein said oligonucleotide comprises one or more ribonucleotides and wherein a said ribonucleotide contains a modification.

9. The method of claim 8, wherein said modification is selected from the group consisting of a 2′

-O-methyl modified ribose.

10. The method of claim 7, wherein said modification is selected from the group consisting of at least one of a peptide nucleic acid, a locked nucleic acid, and morpholino phosphorodiamidate.

19. The method of claim 7 wherein said steroid is a glucocorticosteroid.

20. The method of claim 19 wherein said glucocorticosteroid is selected from a group consisting of prednisone, dexamethasone, prednizolone and deflazacort.

21. The method of claim 20 wherein said prednisone is present at a dosage of 0.5-1.0 mg/kg.

22. The method of claim 20 wherein said deflazacort is present at a dosage of 0.4-1.4 mg/kg

11. A method for increasing the production of a functional dystrophin protein in a cell, said cell comprising pre-mRNA of a dystrophin gene encoding an aberrant dystrophin protein comprising:

providing said cell with a first compound for inhibiting inclusion of an exon selected from the group consisting of;

exon 2, exon 8, exon 43, exon 44, exon 45, exon 46, exon 50, exon 52, exon 53 and exon 55 into mRNA produced from splicing of said dystrophin pre-mRNA, wherein said first compound is an antisense oligonucleotide that induces the skipping of the exon of the human dystrophin pre-mRNA, and

providing said cell with a second compound comprising a steroid,

said method further comprising allowing translation of mRNA produced from splicing of said pre-mRNA;

wherein, upon administration to a DMD or BMD patient, the composition increases the ratio of said dystrophin to laminin-α

2 in muscle tissue of said patient as compared to the ratio of said dystrophin to laminin-α

2 in muscle tissue of a patient administered with said first compound and not said second compound; and

wherein said antisense oligonucleotide is complementary to a portion of the exon that is 13 to 50 nucleotides in length and

wherein said oligonucleotide comprises a non-naturally occurring modification.